Zobrazeno 1 - 10
of 260
pro vyhledávání: ''
Publikováno v:
Cancer chemotherapy and pharmacology
Cancer Chemotherapy and Pharmacology
Cancer Chemotherapy and Pharmacology
Purpose Panitumumab is a human monoclonal antibody targeting the epidermal growth factor receptor for the treatment of wild-type RAS metastatic colorectal cancer (mCRC). Currently, no dedicated clinical studies have evaluated the effect of organ impa
Autor:
Hélène Behal, Anthony Turpin, Simon Baldacci, Enora Vauléon, Renaud Desbarbieux, Nicolas Simon, Marie-Hélène Vieillard, Diane Pannier, Loïc Lebellec
Publikováno v:
Cancer Chemotherapy and Pharmacology. 87:533-541
The occurrence of arthralgia and myalgia during treatment with bevacizumab (Bev) has been described but not spontaneously reported. We aimed to evaluate the frequency of arthralgia in patients treated with Bev and identify the risk factors. In this o
Autor:
Malaz Abutarif, David Jaworowicz, Alexander E. Perl, Jill Fiedler-Kelly, Youngsook Choi, Nigel H. Russell, Siddhartha Ganguly, Alwin Krämer, Ophelia Yin, Mark J. Levis, Samer K. Khaled, Dongwoo Kang, Giovanni Martinelli, Jorge E. Cortes, Elizabeth Ludwig, Hannah Huang
Publikováno v:
Cancer Chemotherapy and Pharmacology
Purpose This analysis evaluated the relationship between concentrations of quizartinib and its active metabolite AC886 and QT interval corrected using Fridericia’s formula (QTcF) in patients with relapsed/refractory acute myeloid leukemia (AML) tre
Autor:
Annamaria Offidani, Anna Campanati, Mariangela Di Vincenzo, Monia Orciani, Giulia Radi, Federico Diotallevi, Miriam Caffarini, Guendalina Lucarini
Publikováno v:
Inflammation Research. 70:79-87
Psoriasis cellular hallmarks, such as the imbalance between Th1/Th17 and Th2 cytokines and the dysregulated expression of vascular endothelial growth factor (VEGF), inducible nitric oxide synthase, (iNOS) and indoleamine 2,3-dioxygenase (IDO), are al
Autor:
Ahmad Awada, Monica Dinulescu, Armin Scheuler, Suzanne Leijen, Jan H.M. Schellens, Nadine Houede, Jean Pierre Delord, Carlos Gomez-Roca, Richard F. Kefford, Giorgio Massimini, Vibeke Kruse, Philippe Aftimos, Thierry Lesimple, Antoine Italiano, Celine Pages, E. Raymond, Sandrine Faivre, Sylvie Rottey, Céleste Lebbé
Publikováno v:
Targeted Oncology. 16:37-46
The Ras/Raf/mitogen-activated protein kinase kinase/extracellular signal-regulated kinase (Ras/Raf/MEK/ERK) signaling cascade is frequently constitutively activated in human cancers. Pimasertib is a selective and potent adenosine triphosphate non-com
Autor:
Rama Suresh, Saiama N. Waqar, Haeseong Park, Benjamin R. Tan, Nikolaos A. Trikalinos, Sarah Larson, Kerry J. Williams, Daniel Morgensztern, A. Craig Lockhart, Andrea Wang-Gillam, Jingqin Luo, Ramaswamy Govindan, Brian A. Van Tine
Publikováno v:
Cancer Chemother Pharmacol
PURPOSE: Resistance to treatment with inhibitors of mammalian target of rapamycin (mTOR) is partially mediated by activation of epidermal growth factor receptor (EGFR). We conducted a phase I study to determine the recommended phase II dose (RP2D) an
Autor:
Takahiro Ebata, Yutaka Fujiwara, Shunsuke Kondo, P. Rietschel, Noboru Yamamoto, Tasha N. Sims, Toshio Shimizu, Akihiko Shimomura, Siyu Li, Anne Paccaly, Takafumi Koyama, Satoru Iwasa, Shigehisa Kitano
Publikováno v:
Cancer Chemotherapy and Pharmacology
Purpose Part 1 of this two-part, open-label, Phase 1 study (NCT03233139) assessed the safety, tolerability, pharmacokinetics, immunogenicity, and clinical activity of cemiplimab in Japanese patients with advanced malignancies. Methods Patients receiv
Autor:
Takashi Osaki, Kyoichi Kaira, Hisao Imai, Kenya Kanazawa, Keita Mori, Satoshi Wasamoto, Yukihiro Umeda, Ou Yamaguchi, Koichi Minato, Shinichi Ishihara, Norimitsu Kasahara, Kensuke Suzuki, Tomohide Sugiyama, Hisashi Ishii, Hiroshi Kagamu, Hiroyuki Minemura, Mie Kotake, Ichiro Naruse, Junji Uchino
Publikováno v:
Cancer Chemotherapy and Pharmacology. 85:761-771
Immune checkpoint inhibitors (ICIs) are an effective subsequent-line treatment for patients with advanced non-small cell lung cancer (NSCLC). However, it remains unclear whether the efficacy and safety of subsequent-line ICI monotherapy in elderly pa
Autor:
Jesús María Hernández-Rivas, Diego Alonso López, Eva Lumbreras, María Abáigar, Beatriz Arrizabalaga, Ana A. Martín, Teresa González, María Díez-Campelo, Jesús María Hernández Sánchez, Sara Erquiaga, Mónica del Rey, Raquel de Paz, Ana Eugenia Rodríguez Vicente
Publikováno v:
Digital.CSIC. Repositorio Institucional del CSIC
instname
instname
The iron chelator deferasirox is widely used in patients with iron overload. Patients with low-grade myelodysplastic syndromes (MDS) get transfusion dependency and need to be treated with deferasirox to avoid iron overload. Moreover, in some patients
Publikováno v:
Cancer Chemotherapy and Pharmacology. 85:113-119
To determine the maximum tolerated dose (MTD) and recommended dose (RD) of modified FLOT regimen (fluorouracil plus leucovorin, oxaliplatin and docetaxel) for treating Chinese patients with metastatic adenocarcinoma of stomach. Chinese patients with